Ajanta Pharma reports Q3 FY2026 revenue up 20% and PAT up 18%, with nine-month revenue up 16% and PAT up 14%, aided by forex-neutral EBITDA growth and strong performance across India, US, and Africa.
AI Assistant
Ajanta Pharma Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.